Bambusa Therapeutics

Bambusa Therapeutics is addressing a variety of dermatological conditions, including atopic dermatitis, CSU, and prurigo nodularis.

Bambusa Therapeutics is building a comprehensive pipeline to address the entire I&I market, including dermatology, respiratory, gastroenterology and rheumatology.

Bambusa Therapeutics is addressing a variety of respiratory conditions, including COPD, asthma, and CRSwNP.

Publications about how Bambusa Therapeutics is engineering tomorrow’s I&I solutions through rigorous scientific research and platform innovation.

Dr. Liang brings deep biopharma finance, strategy, and capital markets expertise to support the company's next phase of growth

Veteran life sciences executive brings more than 30 years of financial, strategic and business experience to support Bambusa's continued growth and

First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31

Detailed findings from a randomized, double-blind, placebo-controlled cohort presented by Eric Simpson, M.D., M.C.R., of Oregon Health & Science University

Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory disorders.

Bambusa Therapeutics uses next-generation bispecific antibodies to advance immunological and inflammatory treatment.

privacy policy for Bambusa Therapeutics

Terms of Use - Bambusa Therapeutics

Bambusa Therapeutics prices its upsized initial public offering (IPO) to raise capital. The clinical-stage biopharmaceutical company focuses on developing novel therapies, though specific details about the offering size or use of funds are not disclosed in the announcement.

Oct 2026Bambusa TherapeuticsNews article

Bambusa Therapeutics raises **$168.9 million** in its IPO by selling more shares at the midpoint of its target range, funding bispecific antibody research and development. Aspen Neuroscience falls short of expectations, selling shares only at the lower end of its IPO range and issuing fewer shares than anticipated.

Oct 2026Fierce BiotechNews article

Bambusa Therapeutics shares **BBT001** proof-of-concept results for atopic dermatitis in a randomized, double-blind, placebo-controlled study. The findings were presented at the **International Society for Atopic Dermatitis (ISAD) 2026** by Eric Simpson, M.D., M.C.R., of Oregon Health & Science University. The trial evaluates the therapeutic’s efficacy in treating atopic dermatitis symptoms.

Oct 2026Bambusa TherapeuticsNews article

Bambusa Therapeutics names **Jonathan I. Lieber** as its new **Chief Financial Officer (CFO)**. Lieber joins with over **30 years of experience** in life sciences finance, strategy, and operations. The appointment aims to bolster the company’s financial leadership as it scales its therapeutic development pipeline.

Oct 2026Bambusa TherapeuticsNews article